Betmiga PR prices fluctuated 3 times Between 15 days

Lower drug prices on the 14th → Increase on the 22nd → Lower again on the 1st of next month

If the suspension of the Supreme Court's execution is cited, there is another possibility of change

Wholesale and retail, such as pharmacies and distribution, and careful attention and preparation for changes in drug prices are required

It is a drug with a lot of stories.

 

Betmiga PR (Mirabegron) of Astellas Pharmaceutical of Korea, which is in a lawsuit with the government to cancel the drug price drop, is a drug with a lot of price fluctuations.

 

The drug has repeatedly filed lawsuits against the government's drug price cut, returning, cutting and raising drug prices as the results of the Price-Volume Agreement and additional calculations are added, with at least three drug price changes expected this month alone.

 

In the aftermath, continued settlement and fluctuations in pharmacies and distributors are expected to follow, signaling chaos.

 

According to the Ministry of Health and Welfare, the price of two Betmiga PR (Mirabegron) items, whose suspension of drug prices was lifted on the 14th, will rise slightly as of the 22nd as the price hike was adjusted this time.

 

The increased price is KRW 314 for Betmiga PR and KRW 471 for 50mg of Betmiga PR.

 

Up to two additional changes from the new generic registration to the new suspension of execution It is now common for drug price changes to occur frequently due to drug price lawsuits against the government.

 

However, Betmiga PR is experiencing price hikes and cuts due to additional criteria, application and cancellation of the Price-Volume Agreement results, and price changes due to further litigation.

 

Since the drug was lowered on the 14th due to the previous ruling of the administrative court (2021a 10434), the government has considered the additional application of the drug.

 

This drug is subject to additional application.

 

Therefore, it was raised to the 22nd by applying an additional calculation as of the standard from the 14th application at the time.

 

In addition, the cancellation of the Price-Volume Agreement conducted earlier this year was reflected, making it different from the drug price (price before 14 days) at the time of the administrative court suit.

 

The company is filing an appeal with the High Court.

 

At the same time, the company raised a suspension to the effect of maintaining the actual initial price, but on the 12th, the High Court did not accept it unusually.

 

However, since the suspension of execution can be carried out separately from the lawsuit on the merits of our law, the company immediately applied for a separate suspension of execution to the Supreme Court, and the results have not yet been released.

 

If the Supreme Court results are decided to cite suspension of execution, the price will change again if the price changes to its original state Price fluctuations do not stop here.

 

As Mirabegron's generic is scheduled to be additionally registered on December 1, the drug price change, which was expected to be adjusted to December 22, will change again in December.

 

In other words, since there are three companies based on registered companies and the number of new generics exceeds three companies, the additional mechanism applied by the government will be lifted and the price will fall again.

 

This is a change in drug prices that has progressed or is scheduled for only 15 days since the application of the administrative court results on the 14th, and the number of times alone is as many as three or up to four times.

 

Confused by frequent fluctuations in drug prices and wholesale and retail prices of pharmacies and distribution prices As a result, the return and settlement of distributors and pharmacies, which are wholesale and retail branches of drugs, and confusion in face-to-face patients are inevitable.

 

First of all, pharmacies should pay attention to discrepancies in claims if they miss the update of drug prices.

 

In addition, it should be notified when facing the patient.

 

In the case of distributors, they must make predictable plans for returns and settlements to check the volume with trading pharmacies and customers.

 

Due to the nature of wholesale and retail dealing with tens of thousands of drugs, such confusion is expected to continue unless the system and law improve.

 

In order to solve such a legal battle, the ruling party is currently pushing for a revision of the law aimed at banning and recovering corporate lawsuits, and the government and insurance authorities are also closely watching it.

 

The MOHW said, "The part to be raised and adjusted as of the 22nd will end on December 1st," adding, "Astellas is appealing to the Supreme Court (related to suspension of execution), so if there is any change, additional information will be provided immediately."